Cargando…
Third line scenario in advanced non-small cell lung cancer: is the anti-angiogenetic strategy the only actor up to now?
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797454/ https://www.ncbi.nlm.nih.gov/pubmed/35117068 http://dx.doi.org/10.21037/tcr.2018.08.23 |
| _version_ | 1784641556969422848 |
|---|---|
| author | Mecca, Caterina Bertaglia, Valentina Novello, Silvia |
| author_facet | Mecca, Caterina Bertaglia, Valentina Novello, Silvia |
| author_sort | Mecca, Caterina |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8797454 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87974542022-02-02 Third line scenario in advanced non-small cell lung cancer: is the anti-angiogenetic strategy the only actor up to now? Mecca, Caterina Bertaglia, Valentina Novello, Silvia Transl Cancer Res Editorial AME Publishing Company 2019-03 /pmc/articles/PMC8797454/ /pubmed/35117068 http://dx.doi.org/10.21037/tcr.2018.08.23 Text en 2019 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/. |
| spellingShingle | Editorial Mecca, Caterina Bertaglia, Valentina Novello, Silvia Third line scenario in advanced non-small cell lung cancer: is the anti-angiogenetic strategy the only actor up to now? |
| title | Third line scenario in advanced non-small cell lung cancer: is the anti-angiogenetic strategy the only actor up to now? |
| title_full | Third line scenario in advanced non-small cell lung cancer: is the anti-angiogenetic strategy the only actor up to now? |
| title_fullStr | Third line scenario in advanced non-small cell lung cancer: is the anti-angiogenetic strategy the only actor up to now? |
| title_full_unstemmed | Third line scenario in advanced non-small cell lung cancer: is the anti-angiogenetic strategy the only actor up to now? |
| title_short | Third line scenario in advanced non-small cell lung cancer: is the anti-angiogenetic strategy the only actor up to now? |
| title_sort | third line scenario in advanced non-small cell lung cancer: is the anti-angiogenetic strategy the only actor up to now? |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797454/ https://www.ncbi.nlm.nih.gov/pubmed/35117068 http://dx.doi.org/10.21037/tcr.2018.08.23 |
| work_keys_str_mv | AT meccacaterina thirdlinescenarioinadvancednonsmallcelllungcanceristheantiangiogeneticstrategytheonlyactoruptonow AT bertagliavalentina thirdlinescenarioinadvancednonsmallcelllungcanceristheantiangiogeneticstrategytheonlyactoruptonow AT novellosilvia thirdlinescenarioinadvancednonsmallcelllungcanceristheantiangiogeneticstrategytheonlyactoruptonow |